Age-related macular degeneration: A two-level model hypothesis.

Age-related macular degeneration Ageing Immune response Inflammation Two-level model

Journal

Progress in retinal and eye research
ISSN: 1873-1635
Titre abrégé: Prog Retin Eye Res
Pays: England
ID NLM: 9431859

Informations de publication

Date de publication:
05 2020
Historique:
received: 26 09 2018
revised: 19 12 2019
accepted: 26 12 2019
pubmed: 4 1 2020
medline: 20 5 2021
entrez: 4 1 2020
Statut: ppublish

Résumé

Age-related diseases, including age-related macular degeneration (AMD), are of growing importance in a world where population ageing has become a dominant global trend. Although a wide variety of risk factors for AMD have been identified, age itself remains by far the most important risk factor, making it an urgent priority to understand the connections between underlying ageing mechanisms and pathophysiology of AMD. Ageing is both multicausal and variable, so that differences between individuals in biological ageing processes are the focus of a growing number of pathophysiological studies seeking to explain how ageing contributes to chronic, age-related conditions. The aim of this review is to integrate the available knowledge on the pathophysiology of AMD within the framework of the biology of ageing. One highly significant feature of biological ageing is systemic inflammation, which arises as a second-level response to a first level of molecular damage involving oxidative stress, mutations etc. Combining these insights, the various co-existing pathophysiological explanations in AMD arrange themselves according to a two-level hypothesis. Accordingly, we describe how AMD can be considered the consequence of age-related random accumulation of molecular damage at the ocular level and the subsequent systemic inflammatory host response thereof. We summarize evidence and provide original data to enlighten where evidence is lacking. Finally, we discuss how this two-level hypothesis provides a foundation for thoughts and future studies in prevention, prognosis, and intervention.

Identifiants

pubmed: 31899290
pii: S1350-9462(19)30112-0
doi: 10.1016/j.preteyeres.2019.100825
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

100825

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Maarten P Rozing (MP)

The Research Unit for General Practice and Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark; Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Jon A Durhuus (JA)

Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.

Marie Krogh Nielsen (M)

Clinical Eye Research Division, Department of Ophthalmology, Zealand University, Hospital, Roskilde and Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.

Yousif Subhi (Y)

Clinical Eye Research Division, Department of Ophthalmology, Zealand University, Hospital, Roskilde and Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.

Thomas Bl Kirkwood (TB)

Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.

Rudi Gj Westendorp (RG)

Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Public Health, Section of Epidemiology, University of Copenhagen, Copenhagen, Denmark.

Torben Lykke Sørensen (TL)

Clinical Eye Research Division, Department of Ophthalmology, Zealand University, Hospital, Roskilde and Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. Electronic address: tlso@regionsjaelland.dk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH